Daiichi Sankyo Launches Ranbaxy’s Antihypertensive in Africa

20 December 2009 (Last Updated December 20th, 2009 18:30)

Daiichi Sankyo has announced it will launch Ranbaxy Laboratories' Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six African countries. The companies will launch the products under the brand name Olvance, in Kenya, Mozambique, Nigeria, Tanzania, Ug

Daiichi Sankyo has announced it will launch Ranbaxy Laboratories' Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six African countries.

The companies will launch the products under the brand name Olvance, in Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia.

Daiichi Sankyo president and CEO Takashi Shoda said that this is the first time Daiichi Sankyo and Ranbaxy have leveraged their business model to release a product in Africa.

Olmesartan Medoxomil helps to lower blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonising the release of hormone that causes salt retention and increased blood volume.

Olmesartan Medoxomil was first launched in India in April 2009 and is available in more than 50 countries worldwide.